All In Biotech

Drug Trial Radar · NCT05739981

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Feb 10, 2023

Primary completion

Jun 30, 2027

Study completion Aug 30, 2028

Sponsor

Lead sponsor
ImunonIndustry
Sponsor type
Industry
Collaborators
Breakthrough Cancer Research
First posted
Feb 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Interventions

  • PaclitaxelDrug

    Paclitaxel 175 mg/m2 IV

  • CarboplatinDrug

    Carboplatin AUC 5-6 IV

  • BevacizumabDrug

    BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.

  • IMNN-001Drug

    IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal Residual DiseaseTime frame: 8 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Medicine SKCCC

    Baltimore, Maryland · Completed

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • OU Health, Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.